Relationship between the Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Brain Tumors

Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play critical roles in regulating processes associated with malignant behavior. These endopeptidases selectively degrade components of the extracellular matrix (ECM), growth factors, and their receptors, contributing to cancer cell invasi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences Vol. 25; no. 5; p. 2858
Main Authors: Dibdiakova, Katarina, Majercikova, Zuzana, Galanda, Tomas, Richterova, Romana, Kolarovszki, Branislav, Racay, Peter, Hatok, Jozef
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01.03.2024
MDPI
Subjects:
Astrocytoma
Brain
Brain cancer
Brain Neoplasms
Brain tumors
Cancer
Care and treatment
Extracellular matrix
Genes
Glioblastoma
Gliomas
Humans
Matrix Metalloproteinase 2 - metabolism
Matrix Metalloproteinase 9 - metabolism
Medical prognosis
Proteases
Proteins
Radiation therapy
RNA
Statistical significance
Tissue Inhibitor of Metalloproteinase-1 - metabolism
Tissue Inhibitor of Metalloproteinases - metabolism
Tumors
United Kingdom
Slovakia
metalloproteinases
tissue inhibitors
brain tumors
immunodetection
qRT-PCR
ISSN:1422-0067, 1661-6596, 1422-0067
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) play critical roles in regulating processes associated with malignant behavior. These endopeptidases selectively degrade components of the extracellular matrix (ECM), growth factors, and their receptors, contributing to cancer cell invasiveness and migratory characteristics by disrupting the basal membrane. However, the expression profile and role of various matrix metalloproteinases remain unclear, and only a few studies have focused on differences between diagnoses of brain tumors. Using quantitative real-time PCR analysis, we identified the expression pattern of ECM modulators (n = 10) in biopsies from glioblastoma (GBM; n = 20), astrocytoma (AST; n = 9), and meningioma (MNG; n = 19) patients. We found eight deregulated genes in the glioblastoma group compared to the benign meningioma group, with only MMP9 (FC = 2.55; p = 0.09) and TIMP4 (7.28; p < 0.0001) upregulated in an aggressive form. The most substantial positive change in fold regulation for all tumors was detected in matrix metalloproteinase 2 (MNG = 30.9, AST = 4.28, and GBM = 4.12). Notably, we observed an influence of TIMP1, demonstrating a positive correlation with MMP8, MMP9, and MMP10 in tumor samples. Subsequently, we examined the protein levels of the investigated MMPs (n = 7) and TIMPs (n = 3) via immunodetection. We confirmed elevated levels of MMPs and TIMPs in GBM patients compared to meningiomas and astrocytomas. Even when correlating glioblastomas versus astrocytomas, we showed a significantly increased level of MMP1, MMP3, MMP13, and TIMP1. The identified metalloproteases may play a key role in the process of gliomagenesis and may represent potential targets for personalized therapy. However, as we have not confirmed the relationship between mRNA expression and protein levels in individual samples, it is therefore natural that the regulation of metalloproteases will be subject to several factors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25052858